Novel associations of VKORC1 variants with higher acenocoumarol requirements. - Wikidata - awgldk - TriplyDB

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

http://www.wikidata.org/entity/Q34731671

about

Uniparental disomy causes deficiencies of vitamin K-dependent proteins.Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge

P2860

Q39343194-042F84A4-B7FC-420C-89D2-66CEF00B7272 Q58695455-E2B2E3C2-0985-4D3F-B79E-3A34432320E4

P2860

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

http://www.wikidata.org/entity/Q34731671

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

@ast

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

@en

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

@nl

type

label

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

@ast

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

@en

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

@nl

prefLabel

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

@ast

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

@en

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

@nl

P1433

Q34731671-4F4A0A14-AFDA-42E5-8197-0FC5885DD69E

P1476

Q34731671-4F5EEB9E-0024-405B-A387-BF2BFBB19672

P2093

Q34731671-0DF4E4AD-7B40-4808-B39F-22D912E0E69A

Q34731671-23F68A67-6A2D-466E-BD41-9BAC55A5485E

Q34731671-50C59B83-83EC-4436-B28C-840ECB93A0D3

Q34731671-67B651C0-27DE-4E7A-8EC3-5FE0C82923AF

Q34731671-84BF7074-52E9-4522-9196-AFA34E07CDB9

Q34731671-B2DEFFFB-F5FE-4074-AACF-26E3D3DAF8F7

Q34731671-BAAF7D6B-F0DA-4D1C-BDE2-3DFA5FD6A1F0

Q34731671-BBA83B47-B563-4952-AFD9-52436FBE60B7

P2860

Q34731671-147EACCE-CDBC-48BE-B318-1ECA2EE2300A

Q34731671-174F623E-C559-44A9-9372-559BD34BF25D

Q34731671-1CD4FFF9-618D-407E-8691-1BFE0061DD4B

Q34731671-1F253BCA-D1AC-4E20-92B9-8F0E1FC7712E

Q34731671-2D27ACFC-C8B9-46E7-90F7-1684D10807EA

Q34731671-2D898A48-D2B4-4378-84CD-480835CAC7B9

Q34731671-315D6280-65C1-4597-8E57-ECA7F49CEAAE

Q34731671-41D0620A-D33B-4C73-8136-16B4E0658865

Q34731671-4F8E784A-459C-425C-B5BD-3DF708548257

Q34731671-5605BC6A-BA89-461F-B912-C1169438FF0E

P304

Q34731671-D12BA407-CFBC-41BC-B2CC-15CFA0CB88EF

P31

Q34731671-9F0DB3EB-FB1C-43E3-AF7C-3305BCE71F7C

P356

Q34731671-85BFCD51-08E1-4F67-BB89-4F08D8CC1622

P407

Q34731671-152FB71C-BC8A-4E79-B39C-7FEDDBA8106D

P433

Q34731671-6B3ED185-0771-44C3-965A-3354562BD809

P478

Q34731671-34004D6A-A284-41CB-A251-0ED764E15F89

P577

Q34731671-A627747F-407A-430C-A819-2EF997407B0F

P5875

Q34731671-76C79664-81F6-461D-AC38-53FFF1111B67

P698

Q34731671-AA188037-DF3E-4350-AF9C-6360292977DB

P932

Q34731671-CCAA164E-ECB6-43FB-9B39-BB79C3D89DD2

P356

JOURNAL.PONE.0064469

P1433

P1476

Novel associations of VKORC1 variants with higher acenocoumarol requirements.

@en

P2093

Ana Isabel Anton

http://www.w3.org/2001/XMLSchema#string

Javier Corral

http://www.w3.org/2001/XMLSchema#string

Jose Padilla

http://www.w3.org/2001/XMLSchema#string

Juan J Cerezo-Manchado

http://www.w3.org/2001/XMLSchema#string

Rocio Gonzalez-Conejero

http://www.w3.org/2001/XMLSchema#string

Vanessa Roldan

http://www.w3.org/2001/XMLSchema#string

Vicente Vicente

http://www.w3.org/2001/XMLSchema#string

Virginia Perez-Andreu

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

Copy number variation detection and genotyping from exome sequence data.

Novel mutations in the VKORC1 gene of wild rats and mice--a response to 50 years of selection pressure by warfarin?

Estimation of the warfarin dose with clinical and pharmacogenetic data.

10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.

A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.

Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

P304

e64469

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0064469

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236925398

http://www.w3.org/2001/XMLSchema#string

P698

23691226

http://www.w3.org/2001/XMLSchema#string

P932

3656883

http://www.w3.org/2001/XMLSchema#string